aj rudowitz – Antitrust Law Blog

A federal district court granted a preliminary injunction preventing the NCAA from enforcing one of its bedrock rules—that member institutions cannot directly compensate student athletes for name, image, and likeness (NIL). For over 100 years, NCAA bylaws prohibited payments to students representing member institutions in intercollegiate games to maintain amateurism across college sports. In recent years, due largely to mounting antitrust losses, the NCAA has allowed college athletes to earn compensation for their NIL but has prohibited compensation by schools and their boosters (so-called NIL collectives) related to the recruiting and transfer process. Believing that those prohibitions likely violate federal antitrust laws and harm students, the Tennessee federal court has preliminarily enjoined the NCAA from enforcing that restriction in State of Tennessee, et al. v. NCAA, No. 3:24-cv-00033.

Continue reading “NCAA Prohibited from Blocking NIL Compensation by Member Schools”

Federal and state antitrust enforcers are keenly focused on potential anticompetitive conduct in the healthcare space.

Federal Trade Commission Chair Lina Kahn recently noted that “the FTC is squarely focused on tackling illegal business practices that deprive Americans of access to affordable and innovative healthcare” in a speech to the American Medical Association’s national advocacy conference. According to Chair Kahn, medical professional consistently express frustration to the FTC “about how the business of healthcare today forces many [medical providers] to subordinate [their] own medical judgment to corporate decision-makers at the expense of patient health.” In response to those complaints, Chair Khan highlighted a few recent enforcement efforts, including scrutiny of group purchasing organizations, drug wholesalers, and pharmacy benefit managers; tackling unlawful consolidation in healthcare markets and roll-ups of healthcare providers. She also touted the FTC’s work protecting healthcare workers, tackling unlawful practices by pharmaceutical companies, including suits to block two major pharmaceutical mergers, and protecting patient privacy and data.

Continue reading “Federal and State Antitrust Enforcers Reiterate Focus on Healthcare”